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Intellectual disability (ID) and autism spectrumdisorders (ASD) are genetically heterogeneous, and a significant number of genes have been
associatedwithbothconditions.A fewmutations inPOGZhavebeenreported inrecentexomestudies;however, these studiesdonotprovide
detailed clinical information.Wecollected the clinical andmoleculardataof 25 individualswithdisruptivemutations inPOGZbydiagnostic
whole-exome, whole-genome, or targeted sequencing of 5,223 individuals withneurodevelopmental disorders (ID primarily) or by targeted
resequencing of this locus in 12,041 individuals with ASD and/or ID. The rarity of disruptive mutations among unaffected individuals (2/
49,401) highlights the significance (p ¼ 4.19 3 1013; odds ratio ¼ 35.8) and penetrance (65.9%) of this genetic subtype with respect to
ASD and ID. By studying the entire cohort, we defined commonphenotypic features of POGZ individuals, including variable levels of devel-
opmental delay (DD) andmore severe speech and language delay in comparison to the severity ofmotor delay and coordination issues.We
also identified significant associations with vision problems, microcephaly, hyperactivity, a tendency to obesity, and feeding difficulties.
Some featuresmight be explained by the high expression of POGZ, particularly in the cerebellum and pituitary, early in fetal brain develop-
ment. We conducted parallel studies inDrosophila by inducing conditional knockdown of the POGZ ortholog row, further confirming that
dosageofPOGZ, specifically inneurons, is essential fornormal learning inahabituationparadigm.Combined, thedataunderscore thepath-
ogenicity of loss-of-function mutations in POGZ and define a POGZ-related phenotype enriched in specific features.Introduction
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Table 1. Clinical Features of Individuals Harboring POGZ Mutations from ID and/or DD Cohorts
UMCN1 UMCN2 UMCN3 UMCN4 UMCN5 UMCN6 UMCN7 UMCN8 UMCN9
Mutation c.2590C>T
(p.Arg864*)
c.3001C>T
(p.Arg1001*)
c.3456_3457del
(p.Glu1154
Thrfs*4)
c.2263del
(p.Glu755
Serfs*36)
c.1152dup
(p.Arg385
Serfs*4)
c.2432þ
1G>A
(p.?)
c.2020del
(p.Arg674
Valfs*9)
c.3847C>T
(p.Gln1283*)
c.3456_3457del
(p.Glu1154
Thrfs*4)
Age (years) 5 13 9 6 2 12 5 26 8
Gender F M M M M M F M M
ID/DD þþ þþ þ/ þ þþ þ þ þþ þ
Speech or
language delay
þþ þþ þþ þ þ þþ þ þþ þþ
Motor delay þ þ þ þ þ þ/ þ þ þ/
ASD þ/ þ þ/ þ/ þ/ þ þ  
Microcephaly þ þ þ  þ  þ/ þ 
Feeding problems ND þ þ þ þ   þ þ
Vision problems  þ þ  þ þ   þ
Obesity tendency ND    þ þ  þ þ
All HGVS annotations were annotated on RefSeq transcript (GenBank: NM_015100.3). A full clinical description for each individual can be found in Table S1.
Abbreviations are as follows: mo., months; ID, intellectual disability; DD, developmental delay; ASD, autism spectrum disorder; M, male; F, female; þ, formal
diagnosis (mild or moderate); þþ, severe presentation; þ/, possessing some features and/or mild presentation; , not present; ND, no data.
ainheritance unknown.focused on cohorts of individuals with either ID or ASD as
the main inclusion criteria. At present, more than 700
genes have been implicated across a wide variety of ID syn-
dromes with diverse clinical presentations,6 and the total
number of ID-associated genes is estimated to be around
2,000.2 Furthermore, over 100 genes have been reported
in syndromic and non-syndromic forms of ASD.7 Not un-
expectedly, many of the same genes underlie both ID
and ASD, suggesting that the molecular networks and
pathways in these disorders are largely overlapping.1
Therefore, similar genetic defects might lead to either ID
or ASD in different individuals or to both conditions in
the same person.
The identification of candidate ID- and ASD-associated
genes has increased tremendously by the widespread
application of next-generation sequencing techniques,
including trio-based whole-exome and whole-genome
sequencing in research and routine clinical diagnos-
tics.8–12 Due to the extensive genetic heterogeneity,
interpretation of pathogenicity of gene mutations is chal-
lenging because establishment of a conclusive molecular
diagnosis is highly dependent on the identification of mu-
tations in the same candidate gene in individuals with
similar phenotypes. This is often hampered by the rarity
of each individual genetic cause of ID and/or ASD. In addi-
tion, even genetic defects in the same gene can be associ-
ated with variable clinical features. To gain insight into
the clinical spectrum of ID and/or ASD phenotypes associ-
ated with genes that have not been previously implicated
in these conditions, it is important to collect clinical and
molecular data from additional individuals.13,14 This can
be facilitated by national and international collaboration542 The American Journal of Human Genetics 98, 541–552, March 3and data sharing of clinical and molecular databases.
Bundling of knowledge and expertise on rare genetic
causes of ID and/or ASD is of great value in the counseling
of individuals. Recently, the core phenotypes of several
distinct syndromes with both ASD and ID as hallmark fea-
tures have been reported.15–18 Here, we report the core
phenotype of a ID and/or ASD syndrome or phenotypic
gestalt, which is caused by disruption of the pogo transpos-
able element with zinc finger domain (POGZ [MIM:
614787]). A small number of mutations in POGZ were
previously reported in different cohorts of individuals
with ASD, ID, or schizophrenia (MIM: 181500); however,
most of these studies did not provide further detailed
clinical, molecular, or functional information on these in-
dividuals, leaving the pathogenicity of these mutations
unclear.12,19–27 Meta-analyses of both small de novo dele-
tions and/or single-nucleotide variants in families affected
by ASD and developmental delay (DD) have shown that
POGZ is likely a risk gene for neurodevelopmental disor-
ders.25,28 Recently, truncating mutations in POGZ have
been reported among small numbers of unrelated individ-
uals. Although the phenotypes were variable, there is
evidence of shared phenotypic features, suggesting that
mutations in this gene might represent a distinct ASD
and/or ID syndrome.29,30
POGZ encodes a heterochromatin protein 1 a-binding
protein containing a cluster of multiple C2H2-type zinc
fingers, a centromere protein (CENP) B-like DNA-binding
domain, and a DDE domain that might regulate gene
expression.20 POGZ is involved in mitosis31 and is ex-
pressed in the human fetal and adult brain (BrainSpan
Atlas and GTEx). It is hypothesized to function as a, 2016
UMCN10 EE3 EE4 FR1 FR2 FR3 FR4 FR5 FR6 EE9a
c.3040C>T
(p.(Gln1014*))
c.2196_2198
delAG
(p.Val733del)
c.2020del
(p.Arg674
Valfs*9)
c.2545þ1del
(p.?)
c.2400dup
(p.Lys801
Glnfs*7)
c.2836del
(p.Asp946
Metfs*12)
c.2574del
(p.His858
Glnfs*13)
c.1810G>T
(p.Glu604*)
c.3001C>T
(p.Arg1001*)
c.2501del
(p.Leu834
Trpfs*20)
11 19 12 4 11 6 6 24 17 11 mo.
F M M M F F F M M M
þ þ þ þþ þ þþ þþ þ þþ þ/
þþ þ þ þþ þ þ þþ þþ þ ND
þ/ þþ þ þþ þ þ þ þ/ þ ND
   þ  þ þ ND þ ND
   þ  þ þ   ND
þ ND  þ  þ ND   ND
 þ þ þ  þ þ ND þ ND
þ þ   þ   þ  NDtranscriptional regulator in molecular networks crucial for
neuronal function.11,19 POGZ has been shown to be co-ex-
pressed with ASD- and ID-associated genes involved in
chromatin remodeling and gene transcription,32 such as
CHAMP1 (MIM: 616327).33
We collected a cohort of 24 individuals with de novo
mutations in POGZ by different approaches, including
whole-exome sequencing in diagnostic and research co-
horts, whole-genome sequencing in a research cohort,
and targeted resequencing in research cohorts. The cohorts
consisted of individuals diagnosed with various neurode-
velopmental disorders, including ID and/or ASD. By study-
ing their phenotype, we were able to further define and
establish the core phenotype associated with disruptive
mutations in POGZ. We provide further support for the
importance of POGZ in cognitive function by utilizing a
Drosophila knockdown model of the POGZ ortholog row.
We found that downregulation of row expression, specif-
ically in neurons, leads to deficits in habituation, a form
of non-associative learning that is highly relevant for
both ID and ASD.Materials and Methods
Individual Selection
Persons with severe POGZ mutations (frameshift, nonsense, and
splice) were identified by different strategies. 12 individuals with
unexplained ID (UMCN1, UMCN3–UMCN10, FR1, FR3, and
FR6), out of approximately 2,413 screened, were identified by diag-
nostic exome sequencing8 (Tables 1 and Table S1). One individual
(UMCN2) was ascertained and published previously from whole-
genome sequencing of 50 individuals with unexplained ID.12The AmeTwo individuals (EE1 and EE2) were identified and published pre-
viously from research exome sequencing of 2,377 simplex families
affected by ASD.10 The remaining ten individuals were identified
by a variety of targeted sequencing techniques. One individual
(FR5) was identified with the Illumina TruSight One panel (Tables
1 and Table S1) from a cohort of 175 individuals with neurodeve-
lopmental disorders. Two individuals (FR2 and FR4) were identi-
fied with a custom SureSelect panel of 275 ID-related genes (Tables
1 and Table S1) from a total of 208 probands with mild to severe
ID. The remaining seven individuals (EE3–EE9) were identified
with molecular inversion probe (MIP)-based sequencing (see
below). Four missense events reported were identified by either
research exome sequencing (in individuals EE11–EE13, reported
previously)10,27 or MIP-based sequencing (in individual EE10).
Subsequent phenotypic follow-up was performed by clinical inter-
view with individuals and families. All experiments carried out on
these individual samples were in accordance with the ethical stan-
dards of the responsible committee on human experimentation
(institutional and national), and proper informed consent was ob-
tained. For identification of disruptive variation in unaffected in-
dividuals, the Exome Aggregation Consortium (ExAC) data were
used with neuropsychiatric cases masked (early access to these
data were provided by DanielMacArthur). This dataset is now pub-
lically available for download on the ExAC portal.
Identification of POGZ Mutations by MIP
Resequencing
Seven individuals with disruptive events and one individual with a
missense event in POGZ were identified with MIP resequencing as
previously described34 from a research cohort of 12,041 individ-
uals with unexplained ID and/or ASD (EE3–EE10). 4,025 sibling
control individuals from the Simons Simplex Collection (SSC)35
and The Autism Simplex Collection (TASC)36 were also screened
as unaffected individuals in this study. In total, we designed 53
small-molecule MIPs to tile across the coding regions and splicerican Journal of Human Genetics 98, 541–552, March 3, 2016 543
junctions of the human POGZ locus. The design and concentra-
tion of each MIP probe used in the pool, as well as their individual
performance, are detailed in Table S2. Secondary Sanger validation
was performed on all individuals and their parents.
Calculation of De Novo Significance and Penetrance
De novo significance was calculated as previously described by
Samocha et al.37 with the R package denovolyzeR (v.3.1.0). To
calculate the significance and penetrance of POGZ likely gene-
disruptive (LGD) mutations in ID and/or DD, we utilized two con-
trol sets as a baseline: the first, representing 45,376 samples, was
composed of the ExAC database with psychiatric cases removed
(ExAC v.0.3) and the second was composed of the 4,025 control
individuals sequenced by MIPs (see above). All significance calcu-
lations were based on the two LGD events found in this composite
collection of 49,401 control individuals and the 25 LGD events
found in 17,264 case individuals included in this study. Case-con-
trol significance was calculated with a standard two-tailed Fisher’s
exact test, and penetrance and its confidence bounds were calcu-
lated with the model described in Rosenfeld et al.,38 specifically:
PðD j GÞ ¼ PðG j DÞ PðDÞ
PðG j DÞ PðDÞ þ PG j D PD0
where D¼ disease, G¼ genotype (the presence of an LGD event in
POGZ), and D ¼ absence of disease. The general population inci-
dence of ID and/or DD in our cohort was assumed to match that
described in Rosenfeld et al. (P(D) ¼ 5.12%), given that our cohort
composition has a similar representation of youth-onset diseases
with an important genetic component with broad exclusion of
chromosomal disorders.
Analysis of GTEx Data
Reads per kilobase of transcript per million mapped reads (RPKM)
values were downloaded from the GTEx portal v.6 on 11 November
2015 and were used to generate boxplots for each of the POGZ iso-
forms included in GENCODE v.19 (NCBI browser GRCh37.p13).
Ensembl identifiers fromGENCODEwere converted to RefSeq iden-
tifiers with the Ensembl portal (release 83). All RefSeq identifiers
referenced here correspond to RefSeq release 73. To test the signifi-
cance of the difference between the average expression of the pitu-
itary and brain subtissues, permutation tests were conducted for
every pair of subtissues. For each pair, we calculated the difference
inmeans, d, and performed 10,000 permutations. In each permuta-
tion, the subtissue labels were randomly swapped and the differ-
ence in means calculated. We then calculated the average of the
difference in means across all shuffles, m. We calculated p values
as (R þ 1) / (N þ 1) where R is the number of times the permuted
difference in themean is further fromm than d andN is the number
of permutations (10,000). Bonferroni’s correction was used to cor-
rect for multiple testing.
Drosophila Knockdown Experiments
Fly stocks were kept on a standardDrosophila diet (cornmeal, sugar,
and yeast) at 25C and 45%–60%humidity at a 12 hr light-dark cy-
cle. The inducible RNAi line against the POGZ Drosophila ortholog
row (vdrc28196, no predicted off-targets) and its genetic back-
ground control line (vdrc60000) were obtained from the Vienna
Drosophila Resource Center.39 For the habituation experiments,
RNAi was induced with the GAL4-UAS system and the panneuro-
nal elav-Gal4 driver linew1118; 2xGMR-wIR; elav-Gal4, UAS-Dicer-2.
The genetic elements in this line suppress eye color as required for544 The American Journal of Human Genetics 98, 541–552, March 3the light-off jump response (2xGMR-wIR)40,41 and increase RNAi
efficiency (UAS-Dicer2), respectively.39 Flies were reared and tested
at 25C and 70% humidity. For qPCR experiments, RNAi was
induced with the ubiquitous actin-Gal4 driver line (w1118; actin-
Gal4/CyOGFP).Drosophila Light-Off Jump Reflex Habituation Assay
The light-off jump habituation assay was performed as previously
described.42 Habituation of the startle jump response toward
repeated light-off stimulus of 3- to 7-day-old individual male flies
was tested in two independent 16-unit light-off jump habituation
systems. 32 flies (16 flies per system) were simultaneously
exposed to a series of 100 short (15 ms) light-off pulses with a
1 s inter-pulse interval. The noise amplitude of wing vibration af-
ter every jump response was recorded for 500 ms after the start of
light-off pulse, and an appropriate threshold was applied to filter
out the background noise. Data were collected and analyzed by a
custom Labview Software (National Instruments). High initial
jumping response to light-off pulse decreased with a growing
number of trials, and flies were considered habituated when
they failed to jump in five consecutive trials (no-jump criterion).
Habituation was scored as the mean number of trials required to
reach the non-jump criterion (trials to criterion [TTC]). The main
effect of the genotype (mutant versus control, corrected for
experimental day and system) on log-transformed TTC values
was tested via linear model regression analysis (lm) with R statis-
tical software (v.3.0.0).Results
Identification of De Novo Mutations in POGZ
Through diagnostic whole-exome sequencing or targeted
exome sequencing, we identified 15 individuals, out of
approximately 2,796 case individuals, with unexplained
ID and LGD mutations in POGZ. In order to identify
additional individuals with POGZ mutations, we targeted
and sequenced the coding portions of this gene by using
MIPs (see Materials and Methods) on a large research
cohort of 12,041 individuals with an ASD and/or ID diag-
nosis and identified seven additional events. Combined
with three events that we previously identified,10,12
we collected 19 individuals with a primary diagnosis of
ID (Tables 1 and Table S1) and 6 individuals with a
primary diagnosis of ASD (Table 2) with LGD mutations
in POGZ (Figure 1 and Table S3). These include 10
nonsense, 12 frameshift, 1 in-frame deletion, and 2 splice
events.
In order to determine the significance of LGDmutations
at this locus in case individuals, we examined several con-
trol cohorts for similar mutations. Using the MIP-based
approach,34 we targeted and sequenced the POGZ locus
in 4,025 unaffected sibling control individuals and identi-
fied no LGD events and one de novo missense event
that has been previously published10 (Table S3). Further-
more, whenwe queried the ExAC database (with neuropsy-
chiatric cases masked), we identified two LGD events
out of 45,376 individuals. Among 29,085 DD cases with
published copy-number variant (CNV) data,43 we observed, 2016
Table 2. Clinical Features of POGZ Individuals from ASD Cohorts
EE1 EE2 EE5 EE6 EE7 EE8
Mutation c.3600_3607dupTGATGACG
(p.Glu1203Valfs*28)
c.3022C>T
(p.Arg1008*)
c.1212C>A
(p.Tyr404*)
c.538C>T
(p.Gln180*)
c.3139G>T
(p.Glu1047*)
c.2291del
(p.Pro764Leufs*27)
Age (years) 8 14 21 7 7 6
Gender M M F F M F
ID/DD þ/ þ þ þ/ þ þ/
Speech or language delay þ þ/ þ þþ þþ þ
Motor delay þ þþ ND ND þ þ
ASD þ þ þ þ þ þ
Microcephaly  þ/    
Feeding problems   ND ND  þ
Vision problems þ ND ND ND þ þ
Obesity tendency þ þ þ/  þ þ
All HGVS annotations were annotated on RefSeq transcript NM_015100.3. A full clinical description for each individual can be found in Table S1.
ID, intellectual disability; DD, developmental delay; ASD, autism spectrum disorder; M, male; F, female; þ, formal diagnosis (mild or moderate); þþ, severe pre-
sentation; þ/, possessing some features and/or mild presentation; , not present; ND, no data.one 8.3 Mbp duplication that subsumed the POGZ locus,
but no gene-breaking CNVs (Figure S1). A similar analysis
of 19,584 control individuals showed no CNVs at this lo-
cus. Previously published studies reported 2 de novo LGD
events among probands with schizophrenia,21,24 16 LGD
events (including one gene-breaking CNV) among cases
of ID, DD, and ASD,20,25,26,29,30 and 1 missense event in
a case of ASD;22 however, none of these overlap directly
with the 25 events reported in this study (Table S3). On
the basis of these data, we estimate that protein-truncating
mutations in POGZ are significantly enriched in ASD and/
or ID individuals in comparison to the general population
(p ¼ 4.19 3 1013, two-tailed Fisher’s exact test; odds
ratio¼ 35.8; 95% confidence interval [CI]¼ 8.9–311.9; sig-
nificance calculations computed solely on the 25 cases
characterized in this study). On the basis of these data,
we estimate the penetrance of POGZ LGD mutations to
be 65.9% (95% CI ¼ 36.4%–89.8%) given the incidence
of ID (5.12%) in the general population.38
24 of the 25 POGZ truncating events were shown to be
de novo, and there was one individual with an LGD event
for whom inheritance status could not be determined
(EE9). Using a previously described statistical framework
for identifying excesses of de novo mutation by gene,37
we estimate the probability of detecting 24 or more
POGZ de novo LGD events in 17,264 cases to be p ¼
5.85 3 1039. In addition to these LGD events, we also
identified a number of missense variants. Exome
sequencing studies previously reported four de novo
missense variants among families with ASD10,22,27 (Figure 1
and Table S3). Two of these events were in probands and
one was in an unaffected sibling control individual. We
identified one additional de novo (Table S4) and two pri-
vate, inherited (Table S5) missense events through our
MIP sequencing efforts.The AmeClinical Description and Phenotype Analysis
The clinical features of the 25 individuals with LGD muta-
tions in POGZ are summarized in Tables 1 and 2 with
accompanying photographs (Figure 2). Detailed case re-
ports are described in the Supplemental Note. Though
most individuals exhibit facial dysmorphisms, there is no
significant pattern that could guide to a recognizable facial
gestalt. However, individuals with disruptive mutations in
POGZ showed a clear overlap in several other clinical fea-
tures. Whereas all had some degree of DD varying from
borderline to severe impairment, most individuals had
mild ID. Speech and language were generally classified as
more severely affected than motor development. Strik-
ingly, in several individuals, the ability to speak in senten-
ces and write and read simple language started very late,
but was eventually acquired. In addition, a distinct neuro-
behavioral phenotype could be recognized, including
either a formal ASD diagnosis or features of ASD and, in
many cases, a seemingly contrary overly social and overly
friendly demeanor. Hyperactivity and sleeping problems
were frequently observed as well. Other medical concerns
included infections, mainly of the upper respiratory tract
at a younger age, and nonspecific ocular problems. In
contrast to the LGD variants, the missense variants are
not clearly associated with impaired intellectual capacity.
However, the missense variants seem to be associated
with a behavioral phenotype, including ASD or autistic-
like features, reminiscent of that seen in individuals car-
rying LGD variants22 (Table S4).
To clarify the phenotype of individuals with the POGZ
mutation, we compared several key phenotypic variables
in the individuals with a POGZmutation and an ASD diag-
nosis to those in a cohort of 2,718 children with ASD from
the SSC.35 The rate of reported problems that emerged
through comprehensive individual follow-up, includingrican Journal of Human Genetics 98, 541–552, March 3, 2016 545
Figure 1. Protein Model of POGZ with Currently Identified Mu-
tations Indicated
All mutations (indicated by individual identifiers that correspond
to Tables 1 and 2 and Tables S1, S3, and S4) have been annotated
on the RefSeq transcript (GenBank: NM_015100.3) (POGZ).
Events in red are LGD and blue are missense. Mutations listed
on the top of the protein structure have not been previously iden-
tified or reported. Mutations listed on the bottom of the protein
structure have been published previously. Protein domains are
indicated on the structure. Abbreviations are as follows: ZNF,
zinc finger; HTH, helix-turn-helix; CC, coiled coil; CHD, congen-
ital heart defect; ASD, autism spectrum disorder; DDD, develop-
mental delay; sib, sibling. Light-gray shaded portions indicate
amino acids omitted by alternatively spliced POGZ transcripts (3,
POGZ isoform; 2, POGZ isoform 2). JMutations for which inheri-
tance is unknown. All other mutations are de novo.sleep problems, feeding problems, vision problems, hyper-
activity, obesity, and microcephaly, were compared across
groups with the Fisher’s exact test (Table S6). It should be
noted that different approaches were used to assess sleep,
feeding, and vision problems in this cohort than were
used in the SSC. For the individuals with a POGZmutation,
the presence of hyperactivity and sleep, feeding, and
vision problems were identified through formal clinical
assessment. For the SSC cohort, sleep, feeding, and vision
problems were established through standardized medical
history interview. Hyperactivity was defined as meeting
clinical cut-off on parent reporting on the Child Behavior
Checklist Externalizing Domain T score.44 Obesity and
microcephaly were determined through examination of
standardized BMI and head circumference values. Sleep
disturbance was not statistically enriched in the POGZ
cohort. Although feeding problems and obesity showed
borderline significance (p ¼ 0.045 and 0.07, respectively),
significant increases in vision problems (p ¼ 0.000067),
microcephaly (p ¼ 0.003), and hyperactivity (p ¼ 0.004)
were observed in the individuals with a POGZ mutation
and ASD relative to the SSC comparison cohort (Table S6).
In this case series, 12 of the 25 individuals (48%) were
identified as clinically obese at some point in the develop-
mental trajectory. This is in contrast to the feeding prob-
lems, including problems with chewing and swallowing
and aversion to solid foods, that were reported in 10 of
the 25 individuals (40%; Tables 1 and 2). For one individ-
ual (EE8), longitudinal growth data were available and
showed that, although other growth measurements (e.g.,
height) were within normal ranges, body weight already
exceeded three SDs above the mean starting at two-and-
a-half years of age. This trend has been maintained
through the age of six (the age of the last recording;546 The American Journal of Human Genetics 98, 541–552, March 3Figure S2A) and is in contrast to this individual’s unaf-
fected sibling, who consumes the same diet and falls
within normal body mass ranges (Figure S2B). The rate of
obesity (i.e., two SDs above the mean) among children
with sporadic ASD is approximately 17% (based on the
SSC), in comparison to 40% in our study (calculation per-
formed only on individuals for whom these data were
available; Table S6).
POGZ Expression Analysis
We explored the normal expression patterns of POGZ
across human tissues by using the publicly available
GTEx database. Of the ten isoforms identified in GTEx,
only two are highly expressed across the majority of tis-
sues: POGZ isoform 3 (GenBank: NM_145796.3) and iso-
form 2 (GenBank: NM_207171.2) (Figures 3A and 3B).
The longest annotated isoform (GenBank: NM_015100.3)
(Figure 3A) does not appear to be constitutively expressed
(not shown). In adult tissues, POGZ isoforms 2 and 3
consistently show significantly increased expression in
the cerebellum and the pituitary gland (p< 0.01, permuta-
tion test; Tables S7 and S8) in comparison to expression
in all other brain subtissues (Figure 3B). The most abun-
dantly expressed RNA isoform 3 (GenBank: NP_665739.
3) (Figure 3B, right panel) differs from the longest anno-
tated isoform of POGZ only by omission of amino acids
112–189 encoded by two in-frame exons that are alterna-
tively spliced out of the mature transcript. All individual
mutations would affect protein isoform 3 of POGZ with
the exception of that of individual EE6 (p.Gln180*;
Figure 1). Isoform 2 (GenBank: NP_997054.1), which
shows the second highest RNA expression pattern
(Figure 3B, left panel), differs from the longest isoform by
omission of amino acids 34–94. This isoform (GenBank:
NM_207171.2) would contain all individual mutations
(Figure 1). Further exploration of POGZ expression in fetal
brain tissues via the BrainSpan Atlas shows that expression
is highest during early embryonic development (9 post-
conception weeks) and decreases gradually until birth,
after which low-level expression is maintained into adult-
hood (Figure 3C).
Modeling POGZ Partial Loss of Function inDrosophila
To gain independent support for the implication of POGZ
in ID/ASD pathologies and address whether the protein is
required directly in neurons for normal functioning, we
turned to the fruit fly Drosophila melanogaster, an organism
that has already been successfully exploited to study spe-
cific aspects of the observed human pathologies.46 The
Drosophila genome harbors a single gene ortholog repre-
senting the human POGZ family (POGZ, ZNF280A-D);
this ortholog is called relative of woc (row).47,48 According
to the ModEncode and FlyAtlas systematic expression da-
tabases,49,50 row is expressed across developmental stages
and tissues, and the highest expression is found in the
larval CNS.38,39 We modeled the POGZ loss-of-function
condition by conditional knockdown of row in Drosophila, 2016
Figure 2. Clinical Photographs of Individuals with De Novo LGD Mutations in POGZ
Individuals harboring POGZmutations show an overlap in facial features, including brachycephaly (not shown) and a broad forehead, a
high nasal bridge, hypertelorism, and a thin upper lip in some. However, the facial phenotype is not very specific or recognizable.
(A and B) Individual UMCN1 at the ages of 1 year (A) and 3 years (B).
(C) Individual UMCN2 at the age of 9 years.
(D and E) Individual UMCN3 at the ages of 4 years (D) and 8 years (E).
(F and G) Individual UMCN4 at the ages of 4.5 years (F) and 5 years, 2 months (G).
(H and I) Individual UMCN6 at the ages of 6 months (H) and 11 years (I).
(J) Individual UMCN7 at the age of 4 years.
(K and L) Individual UMCN8 as a child (K) and at the age of 26 years (L).
(M) Individual UMCN9 at the age of 8 years.
(N and O) Individual UMCN10 at the ages of 4 years (N) and 11 years (O).
(P) Individual EE4 at the age of 12 years.
(Q and R) Individual FR3 at the ages of 7 months (Q) and 6 years (R).
(S) Individual FR4 at the age of 6 years.
(T) Individual EE2 at the age of 14 years.
(U) Individual EE6 at the age of 7 years.
(V) Individual EE7 at the age of 7 years.by using the GAL4-UAS system51 and an inducible RNAi
line.39,51 The efficacy of the row construct was confirmed
by qRT-PCR upon ubiquitous knockdown with the actin-
Gal4 promoter line. The relative mRNA expression
compared to that of the appropriate genetic background
control (the promoter line crossed to the isogenic back-
ground of the RNAi line) was 25% (p ¼ 0.0003; Student’s
t test; Table S9).
In order to assess the consequences of row knockdown in
neurons, we crossed the inducible row RNAi line to the
panneuronal elav-Gal4 promoter line.40,41 The isogenic
host strain of the RNAi construct crossed to the same pro-
moter line served as genetic background controls. We as-
sessed habituation, a non-associative form of learning
and behavioral plasticity, in the light-off jump habituation
paradigm as previously described.42 In this paradigm, the
strong initial reaction to a non-threatening stimulus
(light-off) gradually wanes. Established Drosophila learning
andmemorymutants, as well as severalDrosophila ID-asso-
ciated genemodels, have previously been shown to exhibit
deficits in habituation.40–42,52 row-knockdown flies, as well
as their genetic background controls, showed good initialThe Amejump response (70% of flies jumping in the first five trials),
indicating an absence of severe neurological defects.
Whereas control flies quickly habituated to the repeatedly
presented light-off stimuli (mean TTC ¼ 10.2), the plastic
behavioral response of row knockdown flies was strongly
affected. They needed, on average, more than double the
number of trials to reach the no-jump criterion (n ¼ 135;
mean TTC ¼ 21.57; p ¼ 9.19 3 105). The average jump
response of row-knockdown and control flies, as well as
the difference between mean TTC values, is depicted in
Figure 4. We conclude that partial loss of function of the
POGZ ortholog row in Drosophila neurons specifically
significantly affects non-associative learning in the light-
off jump reflex habituation paradigm.Discussion
We collected a substantial cohort of 24 individuals with de
novo LGD mutations in POGZ, enabling us to define the
core phenotype. Individuals are characterized by a variable
neurodevelopmental or neurobehavioral profile associatedrican Journal of Human Genetics 98, 541–552, March 3, 2016 547
Figure 3. Expression of POGZ Is Highest
in Cerebellum and Pituitary Tissues
(A) Gene models of three RefSeq POGZ iso-
forms. Isoform 1, the longest isoform, is
shown on top (GenBank: NM_015100.3),
isoform 2 in the center (GenBank:
NM_207171.2), and isoform 3 on the bot-
tom (GenBank: NM_145796.3). Exons are
shown as blocks and directionality as
light-gray arrows. Exons in red contain
a mutation identified in this study.
Black stars indicate exons in which disrup-
tive mutations were identified in control
individuals.
(B) Expression of POGZ shown by isoform
(GenBank: NM_207171.2 on the left and
GenBank: NM_145796.3 on the right),
and subtissue from the GTEx database
(v.6).45 Cerebellar tissues are shown in red
and the pituitary gland is shown in blue.
The red dashed line indicates reads per kilo-
base of transcript per millionmapped reads
(RPKM) of 25.
(C) POGZ average expression of all brain
subtissues across brain development (with
RNA-seq RPKM values from the BrainSpan
Atlas v.10; shown in red from 8 post-
conception weeks to 40 years of age). Birth
is indicated by a vertical gray dashed line,
and the mean expression across all time
points is indicated by a horizontal black
dashed line.with ID and/or either autistic features or a formal diagnosis
of ASD. As expected, all individuals showed evidence of
DD ranging from mild to severe. Language and speech
delay presented more prominently than motor delay and
coordination problems. 50% of the individuals reported
here received a formal diagnosis of ASD; however, several
individuals showed an atypical behavioral phenotype
including overly friendly and overly social behavior and
hyperactivity. Other significant phenotypic features were
specific feeding difficulties that seemed to be related to
oversensitivity of the oral region in several individuals, a
tendency to obesity, nonspecific vision problems, and
microcephaly. These clinical finding are also consistent548 The American Journal of Human Genetics 98, 541–552, March 3, 2016with other recent reports of smaller
cohorts of individuals with POGZmu-
tations.29,30
We repeated the phenotypic anal-
ysis, limiting it to those 12 individuals
with a diagnosis of autism, and
compared it to phenotypic data
collected for 2,718 children from the
SSC35 ascertained for the presence of
an ASD diagnosis. Significant in-
creases in vision problems, hyperac-
tivity, feeding problems, and micro-
cephaly (p < 0.05) and a trend
toward obesity (p ¼ 0.07) were
observed in the individuals with a
POGZ mutation relative to the SSCcomparison cohort (Table S6). As has been observed for
other autism risk genes (CHD8 [MIM: 610528], DYRK1A
[MIM: 600855], and ADNP [MIM: 611386]), these data
argue that autistic individuals harboring POGZ mutations
represent not only a distinct genetic but also a clinical sub-
type of the condition defined by a gestalt of features.
It is interesting that POGZ was one of 21 genes recently
highlighted as being recurrently mutated in individuals
with congenital heart disease (CHD [MIM: 600001]) and
neurodevelopmental disorders.53 Homsy et al. considered
the fact that POGZ mutations were also observed in co-
horts of individuals with ASD and/or ID as strong evidence
that CHD and neurodevelopmental disorders share a
Figure 4. Knockdown of the Drosophila POGZ Ortholog row Affects Non-Associative Learning in the Light-Off Jump Reflex Habitua-
tion Paradigm
Jump responses were induced by repeated light-off pulses (100 trials) with a 1 s inter-trial interval. row knockdown flies (rowvdrc28196;
genotype: w1118; 2xGMR-wIR/þ; UAS-rowvdrc28196/elav-Gal4, UAS-Dicer-2) are plotted in red, and genetic background control flies (con-
trol; genotype: w1118; 2xGMR-wIR/þ; elav-Gal4, UAS-Dicer-2/þ) are plotted in dark gray. Linear regression model analysis revealed that
flies with panneuronally-induced row knockdown habituated significantly slower (fold-change ¼ 2.1;***p < 0.001).
(A) Average jump response (% of jumping flies) across 100 light-off trials.
(B) Mean TTC of rowvdrc28196 (TTC ¼ 21.57, n ¼ 135) versus mean TTC of control flies (TTC ¼ 10.2, n ¼ 107). Error bars indicate SEM.common genetic etiology. Two de novo variants were iden-
tified in the CHD study, including one early splice and one
missense event (Figure 1 and Table S3). In our cohort, only
one of the 25 individuals (FR1) with an LGD mutation
showed evidence of CHD (see Supplemental Note), and
subsequent clinical follow-up of seven individuals for
this phenotype provided no evidence of CHD. Interest-
ingly, individual FR1 represented one of two splice muta-
tions in our cohort of individuals with POGZ mutations.
Although pleiotropic effects remain a possibility, an
alternate hypothesis is that POGZ associates with the neu-
rodevelopmental disease aspect and that CHD is caused by
some additional risk factor in the CHD exome-sequencing-
study individuals, given that many suffered from both
neurodevelopmental delay and CHD.
In this study, we report three instances of the same de
novo LGD mutation found in two unrelated individuals
(at amino acid 674 in two individuals, at amino acid
1001 in two individuals, and at amino acid 1154 in two in-
dividuals). These events have not been reported previously
in control samples or other studies.29,30,53 In some cases
(particularly at amino acid 1154), these individuals show
similar phenotypes, including behavioral deficits, but at
the other two sites, the pairs of individuals do not appear
to be more clinically similar. These data suggest that vari-
able expressivity overrides allelic heterogeneity with
respect to phenotypic manifestation, possibly as a result
of differences in the genetic background or environmental
effects. Nevertheless, the identification of identical de
novo events is rare among unrelated affected probands.10
The presence of recurrent events in this study suggests
that there might be a shared mechanism by which these
mutations occur which will require further study to eluci-
date. For example, the mutation at amino acid 674 repre-
sents a CpG dinucleotide, a known hotspot for de novo
mutation.54
We find that POGZ is constitutively expressed across
most tissues and has significantly higher levels of expres-The Amesion in the cerebellum and the pituitary gland (Figure 3
and Tables S7 and S8). Also, in Drosophila, row mRNA
expression is observed across most tissues, and the stron-
gest signal is in the CNS. The cerebellum is known to regu-
late motor control and some cognitive functions and has
been implicated in the biology of ASD as well as related
conditions, such as attention deficit hyperactive disorder
(ADHD [MIM: 143465]).55 Among individuals with POGZ
mutations, we observed marked language deficits, delayed
motor development, and lack of coordination, as well as
hyperactivity in some individuals, consistent with the inti-
mate association of the cerebellum and cerebral cortex
with respect to ASD pathology.56 The higher level of
expression in the pituitary also warrants further investiga-
tion in light of the findings of obesity, feeding problems,
and vision deficits in these individuals. Hypothalamic-pi-
tuitary structural lesions in pediatric individuals, for
example, are strongly associated with endocrine dysfunc-
tion, neuro-opthalmic presentation, and abnormal BMI
and growth velocity.57 Notably, we did not observe any in-
dividual in whom both feeding problems and obesity were
present concurrently (Tables 1 and 2). Considering the po-
tential importance of the pituitary, a future area of investi-
gation might be to measure growth hormone production
in individuals with POGZ mutations.
It is interesting that many of the potentially pathogenic
mutations fall within the second half of the protein, sug-
gesting that the protein domains located here might be
responsible for some of the shared phenotypic features.
Although little is known about the function of POGZ
in vivo, two functional domains have been reported in
the literature to lie within this region. The HP1-binding
zinc-finger-like motif (amino acids 791–850) is thought
to be integral for the binding of POGZ to heterochromatin
protein 1 (CBX5, or HP1) for proper mitotic progression.31
When POGZ is knocked down in human cell lines, proper
cell growth and division is abrogated.31 A second protein
domain, the transposase-derived DDE domain (aminorican Journal of Human Genetics 98, 541–552, March 3, 2016 549
acids 1117–1323) near the C-terminal end of the protein, is
known to interact directly with PSIP1 (a.k.a., LEDGF, or
p75),58 which is known to have human expression in the
fetal brain and is thought to be a transcriptional co-acti-
vator involved in neurogenesis.59 Seizures were also a co-
morbidity reported in three individuals with POGZ muta-
tions. These cases represent three of the four earliest
truncating events in the protein that would effectively
lack all of the putative functional domains.
In addition, we studied the effect of POGZ loss of func-
tion in a Drosophila model. Although human POGZ and
Drosophila row share low overall sequence conservation at
the protein level (10% identity), the central zinc finger mo-
tifs are well conserved (25% identity). Given the evolu-
tionary divergence between vertebrates and invertebrates,
such divergence is not unexpected among orthologs but
does limit functional extrapolations given that these differ-
ences could have had effects on protein function. The pro-
teins fulfill the reciprocal best BLAST hit criterion and are
annotated orthologs on the Ensembl and Treefam data-
bases. Moreover, human POGZ and Drosophila row show
conserved protein interactions, such as CBX5/HP1,31
ZMYM4/Wok,60 and NFX1/Nfx261 (human/Drosophila
protein symbol). Targeting Drosophila row revealed defects
in habituation, a form of non-associative learning. This
learning defect is not only relevant to the human ID
phenotype of individuals with POGZ mutations, but also
interesting in light of the co-occurring ASD. Habituation
has been recently proposed as a potential mechanism un-
derlying deficits in predictive coding in ASD, and the abil-
ity to suppress the response to known irrelevant sensory
stimuli might be required for the prevention of overstimu-
lation and salience in ASD individuals.62
In summary, we conclude that POGZ adds to the large
number of proteins implicated in ID and ASD etiology pre-
sent in protein complexes that act by modifying chro-
matin structure and gene regulation.32 The phenotypic
similarities of the individuals also predict a clinical subtype
of ASD and/or ID distinct from that of individuals more
generally diagnosed with autism. The enrichment of spe-
cific features but variability of phenotypic presentation is
reminiscent of other mutations, especially large CNVs,
associated with ASD and/or ID.4 We estimate that de
novo LGD mutations of POGZ might describe up to
0.14% of individuals with undefined ASD and/or ID. Based
on our ascertainment, we conclude that the frequency of
de novo LGD mutations is 3- to 4-fold higher in ID and/
or DD than in ASD, whichmight explain some of the atyp-
ical ASD cases observed in this study. Indeed, ID is a comor-
bidity often associated with ASD (present in 31% of the
SSC individuals);35 all of the individuals with POGZmuta-
tions in this study showed borderline-moderate ID, even
those recruited on a primary ASD diagnosis (Table 2).
Further identification of individuals with disruptive de
novo mutations in POGZ will be required to determine
whether mutations in this gene also lead to ASD in the
range of normal IQ.550 The American Journal of Human Genetics 98, 541–552, March 3Supplemental Data
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